20 gynecological Chinese patent medicine into pharmacies sweet and pastry!

Recently, Tasly issued an announcement stating that the company's exclusive category of Chinese medicine 1.
1, Kunxinning granules, has been approved.
Since 2019, only 2 gynecological Chinese patent medicines have been approved for marketing
.
The latest data from Minai.
com shows that in 2021, the sales of gynecological Chinese patent medicines in physical pharmacies in key cities are expected to increase slightly year-on-year, and gynecological menstrual regulation drugs and gynecological inflammation drugs are still the two main forces
.
From the urban structure, the four major cities of "Beijing, Shanghai, Guangzhou and Shenzhen" have the hottest sales; from the manufacturer structure, Zhuzhou Qianjin Pharmaceutical, Shanxi Guangyuyuan Sinopharm, Sichuan Enwei Pharmaceutical, Beijing Tongrentang Co.
, Ltd.
, Tongrentang Pharmaceutical, and Shandong Buchang Shenzhou Pharmaceuticals rank among the top five; among the TOP20 products, 11 are exclusive.
The growth rates of Zishen Yutai Pills, Kuntai Capsules, Jinfeng Pills, and Kushen Gel have all exceeded 20%; among the TOP20 brands, Shanxi Guangyuyuan Sinopharm Dingkundan from Sichuan Enwei Pharmaceutical, Jieryin Lotion from Sichuan Enwei Pharmaceutical, and Baofukang Suppository from Hainan Bikai Pharmaceutical rank in the top three.
From the perspective of the number of brands, Zhuzhou Qianjin Pharmaceutical has the most
.
Tasly’s blockbuster class 1 new drug is coming, and only 2 gynecological Chinese patent medicines have been approved in the past 3 years.
Basic information of Kunxinning granules.
, The product is indicated for female menopausal syndrome
.
According to the data, according to the "Consensus of Experts on the Management of Menopausal Women's Health (Basic Edition)", the current drug treatment of menopausal syndrome is mainly divided into two categories: Chinese medicine treatment and menopausal hormone treatment.
Chinese medicine treatment can achieve a certain effect on menopausal symptoms, especially suitable for menopausal symptoms.
Women who are willing to receive menopausal estrogen therapy and women who have contraindications to estrogen therapy
.
In recent years, the women's menopausal medication market has grown steadily, and Kunxinning granules can meet the unmet clinical needs of patients with relevant indications after they are marketed
.
Source of gynecological Chinese patent medicines approved since 2019: Meinenet MED2.
0 Chinese drug review database From 2019 to present, the only gynecological Chinese patent medicines are Jinrong Xiaopi Granules from Guangzhou Kangyuan Pharmaceutical and Kunxinning Granules from Tasly 2 A product was approved for listing
.
Up to now, 6 new gynecological Chinese patent medicines including Gongyankang gel from Jiangxi Baishen Changnuo Pharmaceutical, Qiling Wenshen Xiaosang Granules from Tasly, and Xianghu Dangxiong Xingtiao Capsules from Wuhan Hengxinyuan Pharmaceutical have been clinically approved.

.
"Beijing, Shanghai, Guangzhou and Shenzhen" has the hottest sales! Qianjin, Guangyuyuan, and Enwei "lead" the retail market of gynecological Chinese patent medicine in 2021E key city physical pharmacy gynecological Chinese patent medicine city pattern (unit: 10,000 yuan) Source: Mi Nei.
com Key city physical pharmacy terminal competition pattern Mi Nei.
The market sales of gynecological Chinese patent medicines in physical pharmacies in key cities have exceeded 1.
7 billion yuan, and it is expected to increase slightly year-on-year in 2021
.
From the perspective of the urban structure, the sales of the four major cities in Beijing, Shanghai, Guangzhou and Shenzhen are among the top four.
Among them, Guangzhou won the "sales crown" throne with sales of nearly 200 million yuan.
In addition, sales in six cities including Shenzhen, Shanghai and Beijing The amount is above 100 million yuan
.
From the perspective of manufacturers, Zhuzhou Qianjin Pharmaceutical, Shanxi Guangyuyuan Sinopharm, Sichuan Enwei Pharmaceutical, Beijing Tongrentang Co.
, Ltd.
Tongrentang Pharmaceutical, and Shandong Buchang Shenzhou Pharmaceutical rank in the top five, with a combined market share of nearly 30%
.
Subcategory pattern of gynecological Chinese patent medicines in 2021E key city physical pharmacies Source: Mi Nei.
com’s key city entity pharmacies terminal competition pattern From the perspective of sub-category pattern, gynecological inflammation drugs and gynecological menstrual modulators have been the two main forces for many years, with a total market share of more than 80%
.
In terms of growth rate, gynecological antifetal drugs are the fastest, with a year-on-year increase of more than 30%
.
11 exclusive products seize the TOP20, and the 4 Qianjin brands are eye-catching 2021E key city entity pharmacies gynecological Chinese patent medicine products TOP20 Source: Meinenet key city entity pharmacies terminal competition pattern Note: * is the exclusive TOP20 products, 11 are exclusive products, 9 pharmaceutical companies including Zhuzhou Qianjin Pharmaceutical, Sichuan Enwei Pharmaceutical, Shandong Buchang Shenzhou Pharmaceutical, Hainan Bikai Pharmaceutical, and Guiyang Xintian Pharmaceutical are involved
.
It is worth mentioning that there are as many as 5 exclusive products in the top ten products, including Jieeryin Lotion, Baofukang Suppository, Zishen Yutai Wan, Tongren Wuji Baifeng Wan, and Gynecological Qianjin Tablets
.
In terms of growth rate, Zishen Yutai Pills, Kuntai Capsules, Jinfeng Pills, and Kushen Gel all exceeded 20%.
Among them, Zishen Yutai Pills had the fastest growth rate, approaching 40%.

.
From the perspective of sub-categories, gynecological menstruation regulating drugs have the most, with 9; followed by gynecological inflammation drugs, with 8
.
2021E key city entity pharmacy gynecological Chinese patent medicine brand TOP20 Source: Meinenet key city entity pharmacy terminal competition pattern of TOP20 brands, Shanxi Guangyuyuan Sinopharm's Dingkundan, Sichuan Enwei Pharmaceutical's Jieryin Lotion, Hainan Bikai Medicine Baofukang Suppository of the industry ranks in the top three; from the perspective of the number of brands, Zhuzhou Qianjin Pharmaceutical has the most, with 4, adding Jiawei Xiaoyao Pills compared with last year
.
Zishen Yutai Pills is the exclusive gynecological Chinese patent medicine of Baiyunshan Zhongyi Pharmaceutical.
According to data from Minaiwang, the market share of Zishen Yutai pills in physical pharmacies in key cities has increased rapidly in recent years, from less than 1% in 2018 to 2021.
It is expected to exceed 3%
.
According to data, Zishen Yutaiwan won the former Ministry of Health's major scientific and technological achievements B award, and was selected as recommended medicines such as "Chinese Medicine Gynecology", "Chinese Medicine Gynecology Common Diseases Diagnosis and Treatment Guide"
.
Baiyunshan Zhongyi Pharmaceutical puts forward a development strategy to build a "gynecological drug production base".
Zishen Yutai Pill is one of the key products of Baiyunshan Zhongyi Pharmaceutical and Guangzhou Pharmaceutical Group's strategic planning
.
Currently, Zishen Yutai Pill has been approved for clinical trial applications for increasing the function of "decreased ovarian reserve"
.
Among the TOP20 brands, Zhuzhou Qianjin Pharmaceutical has 4 products on the list, including Gynecological Qianjin Tablets, Gynecological Qianjin Capsules, Yimu Granules, and Jiawei Xiaoyao Pills.
Among them, Gynecological Qianjin Tablets and Gynecological Qianjin Capsules are exclusive products
.
According to data from Mi Nei.
com, the market share of gynecological Qianjin tablets in physical pharmacies in key cities has steadily increased in recent years
.
In addition, Zhuzhou Qianjin Pharmaceutical's Jiawei Xiaoyao Pills ranked among the TOP20 brands, with sales increasing by nearly 15% year-on-year
.
Qianjin Pharmaceutical pointed out in the 2021 semi-annual report that for retail terminals, the company’s pharmacy marketing department has strengthened cooperation with chain pharmacies and individual pharmacies across the country, and formulated different cooperation plans based on the characteristics of chain pharmacies to meet the needs of chain differentiation.
Ensure that products reach various retail terminals through channel distribution
.
Through intensified consumer education, store staff training, brand promotion and other store promotion activities, the company will continue to maintain steady growth at the retail end in the first half of 2021
.
In addition to gynecological Qianjin tablets/capsules, products such as Yimu Granules and Jiawei Xiaoyao Pills have grown rapidly at the retail end, and their market position has been further strengthened
.
Source: Meinenet database, company announcement Note: The terminal competition pattern of physical pharmacies in key cities of Meinenet is based on the sales data of all physical pharmacies in 22 key cities, including Beijing, Shanghai, Guangzhou, and Shenzhen, and continuously monitors the entire category Sample city medication database
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Please correct me if there are any errors or omissions
.